My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
April 2016
POLICY AND ADVOCACY
Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria Issues Assessment of National Action Plan
The Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) last month unveiled their initial report and recommendations (PDF) on federal efforts to address antimicrobial resistance (AR). Several IDSA priorities were included: 
  • Establishing a Limited Population Antibacterial Drug (LPAD) approval mechanism for antibiotics to treat a serious or life-threatening infection for which there is an unmet medical need. 
  • Providing economic incentives (including tax credits) necessary to facilitate the research and development (R&D) and appropriate use of urgently needed new antibiotics and diagnostics. 
  • Investing in a strong ID physician workforce to implement key objectives in the National Action Plan for CARB, including leading antibiotic stewardship programs and conducting research and development for new antibiotics, diagnostics and vaccines. 
  • Providing robust federal funding for each of the agencies with responsibilities for implementing the National Action Plan for CARB. 
  • Strengthening data collection and surveillance of antibiotic use and antibiotic resistance in human and animal health settings. 
  • Expanding global coordination of AR activities, including surveillance and R&D. 
Sylvia Matthews Burwell, Secretary of Health and Human Services, also recently asked PACCARB (PDF) to comment on antibiotic, diagnostic and vaccine incentives as well as on prioritizing federal investments in AR. IDSA will continue to promote the work of PACCARB and the administration, as implementation of the National Action Plan continues forward.


< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


PATIENT CARE AND SCIENCE
Lyme Disease Guideline Panel Responds to Public Comments
What ID Researchers Should Know About PCORI Funding
National Academies Seeks to End Transmission of Hepatitis B and C in US
CLINICAL PRACTICE MANAGEMENT
Now’s the Time to Double-Check CMS’s Data on You
Have a Question About Billing and Coding? Ask the Coder Can Help!
CMS Waives Certain Restrictions for Telehealth Services
New Resource Guide for HIV/AIDS Care Providers on Billing and Reimbursement
POLICY AND ADVOCACY
IDSA, HIVMA Advocate for Funding for Antimicrobial Resistance, HIV, Other ID Programs
Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria Issues Assessment of National Action Plan
Senate Committee Advances New Antibiotic Pathway and other ID Bills
Ryan White Care Providers Take to the Hill
HIVMA Hails the First U.S. HIV+ to HIV+ Organ Transplant
GLOBAL ID
IDSA’s Continued Work on Zika Virus
Science Speaks Reports a Range of Developments in Global Infectious Diseases
EDUCATION AND RESOURCES
New ABIM Survey Indicates Physician Interest in Potential Changes to MOC Assessment
ABIM Seeks Physician Input into Open Book Assessments
YOU AND YOUR COLLEAGUES
Journal Club Seeks Additional Members
Polish-Speaking Member Needed for Translation Assistance
Members on the Move
Member Report
FROM THE PRESIDENT
From the President: Christopher D. Busky, CAE Named Next CEO of IDSA
TOP STORIES
IDSA and SHEA Release New Guideline on Antibiotic Stewardship
IDSA Adopts All-In Match Policy
IDWeek Mentorship Program
Journal Club
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.